Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine
Status:
Completed
Trial end date:
1990-05-01
Target enrollment:
Participant gender:
Summary
To determine if the pharmacokinetics of low doses of zidovudine (AZT) (that is, how fast AZT
reaches the blood, what concentration of AZT is attained in the blood, and how long AZT
remains in the blood) changes from day-to-day in the same patient. Also to determine whether
the pharmacokinetics of AZT is changed by sulfamethoxazole/trimethoprim (SMX/TMP) given at
the same time or whether the pharmacokinetics of SMX/TMP is altered by AZT therapy. AZT has
been effective in treating some patients with AIDS, and SMX/TMP is an antibiotic combination
which is useful in preventing or treating Pneumocystis carinii pneumonia (PCP), which is an
important cause of disease and death in patients with AIDS. It is important to know how drugs
interact in patients because addition of a second drug may change the speed at which a drug
is eliminated from the body, and cause increased toxic effects or decreased therapeutic
effects.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination Zidovudine